Other transfer or payment: SIF Stream 1- R&D
Novocol Pharmaceutical of Canada Inc.
$32,716,000.00
Novocol Biomanufacturing Expansion Project (COVID-19)
FY 2020-21 · 2021-03-01
Summary
This project will support the expansion of existing bio-manufacturing facilities and increasing fill-finish capacity for vaccines/therapies, including live and viral vector vaccines.
Program
SIF Stream 1- R&D
Location
Cambridge, Ontario, Canada
Recipient Type
For-profit organization
Business Number
103950481
Type
Other transfer or payment
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-03-01 | 2020-21 | $32,716,000.00 |
| 1 | 2021-03-01 | 2020-21 | $32,716,000.00 |
As published
Agreement End Date
2023-12-31
Agreement Number
815860
Agreement Start Date
2021-03-01
Agreement Title
Novocol Biomanufacturing Expansion Project (COVID-19)
Agreement Title (French)
Projet d’expansion de la biofabrication de Novocol (COVID-19)
Agreement Type
Other transfer payment
Agreement Value
$32,716,000.00
Amendment Date
2023-11-16
Amendment Number
1
Description
This project will support the expansion of existing bio-manufacturing facilities and increasing fill-finish capacity for vaccines/therapies, including live and viral vector vaccines.
Description (French)
Ce projet soutiendra l'expansion des installations de biofabrication actuelles et l'augmentation de la capacité de remplissage-finissage pour les vaccins/thérapies, y compris les vaccins vivants et à vecteur viral.
Federal Riding
Cambridge
Federal Riding (French)
Cambridge
Federal Riding Number
35016
NAICS Code
325410
Organization Code
ic
Organization
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
Program Name
SIF Stream 1- R&D
Program Name (French)
FIS Volet 1- R&D
Program Purpose
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
Program Purpose (French)
-favoriser les activités de R-D qui accéléreront le transfert de la technologie et la commercialisation de produits, de processus et de services novateurs ;-faciliter la croissance et l'expansion des entreprises au Canada ;-attirer et conserver des investissements de grande envergure au Canada ; et-faire progresser la recherche industrielle, le développement et la démonstration de technologies grâce à la collaboration entre les universitaires, les organisations à but non lucratif et le secteur privé.
Recipient Business Number
103950481
Recipient City
Cambridge
Recipient Country
CA
Recipient Legal Name
Novocol Pharmaceutical of Canada Inc.
Recipient Operating Name
Novocol Pharma
Recipient Postal Code
N1R6X3
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
033-2020-2021-Q4-815860
